American Journal of Ophthalmology
Volume 149, Issue 2 , Pages 307-315.e2 , 1 February 2010

Standard-Fluence versus Low-Fluence Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Nonrandomized Clinical Trial

  • Michele Reibaldi

      Affiliations

    • Department of Ophthalmology, University of Catania, Catania, Italy
    • ,
  • Nicola Cardascia

      Affiliations

    • Department of Ophthalmology, University of Bari, Bari, Italy
    • ,
  • Antonio Longo

      Affiliations

    • Department of Ophthalmology, University of Catania, Catania, Italy
    • ,
  • Claudio Furino

      Affiliations

    • Department of Ophthalmology, University of Bari, Bari, Italy
    • ,
  • Teresio Avitabile

      Affiliations

    • Department of Ophthalmology, University of Catania, Catania, Italy
    • ,
  • Salvatore Faro

      Affiliations

    • Department of Ophthalmology, University of Catania, Catania, Italy
    • ,
  • Marisa Sanfilippo

      Affiliations

    • Department of Ophthalmology, University of Catania, Catania, Italy
    • ,
  • Andrea Russo

      Affiliations

    • Department of Ophthalmology, University of Catania, Catania, Italy
    • ,
  • Maurizio Giacinto Uva

      Affiliations

    • Department of Ophthalmology, University of Catania, Catania, Italy
    • ,
  • Ferdinando Munno

      Affiliations

    • Department of Ophthalmology, University of Catania, Catania, Italy
    • ,
  • Vincenzo Cannemi

      Affiliations

    • Department of Ophthalmology, University of Catania, Catania, Italy
    • ,
  • Marco Zagari

      Affiliations

    • Department of Ophthalmology, University of Catania, Catania, Italy
    • ,
  • Francesco Boscia

      Affiliations

    • Department of Ophthalmology, University of Bari, Bari, Italy
    • Corresponding Author InformationInquires to Francesco Boscia, Department of Ophthalmology, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy

,Accepted 19 August 2009.

References 

  1. Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86:126–145
  2. Ober MD, Yannuzzi LA, Do DV, et al. Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology. 2005;112:2088–2094
  3. Jalkh AE, Jabbour N, Avila MP, et al. Retinal pigment epithelium decompensation. I (Clinical features and natural course). Ophthalmology. 1984;91:1544–1548
  4. Ie D, Yannuzzi LA, Spaide RF, et al. Subretinal exudative deposits in central serous chorioretinopathy. Br J Ophthalmol. 1993;77:349–353
  5. Yannuzzi LA, Shakin JL, Fisher YL, Altomonte MA. Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology. 1984;91:1554–1572
  6. Iida T, Yannuzzi LA, Spaide RF, et al. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina. 2003;23:1–7
  7. Ficker L, Vafidis G, While A, Leaver P. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol. 1988;72:829–834
  8. Guyer DR, Yannuzzi LA, Slakter JS, et al. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol. 1994;112:1057–1062
  9. Spaide RF, Hall L, Haas A, et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina. 1996;16:203–213
  10. Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology. 2002;109:1723–1725
  11. Fabianovà J, Porubskà M, Cepilovà Z. Central serous chorioretinopathy—treatment with beta blockers [in Slovak]. Cesk Slov Oftalmol. 1998;54:401–404
  12. Burumcek E, Mudun A, Karacorlu S, Arslan MO. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology. 1997;104:616–622
  13. Yannuzzi LA, Slakter JS, Kaufman SR, Gupta K. Laser treatment of diffuse retinal pigment epitheliopathy. Eur J Ophthalmol. 1992;2:103–114
  14. Chan WM, Lam DS, Lai TY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003;87:1453–1458
  15. Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiographyguided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003;23:288–298
  16. Battaglia Parodi M, Da Pozzo S, Ravalico G. Photodynamic therapy in chronic central serous chorioretinopathy. Retina. 2003;23:235–237
  17. Canakis C, Livir-Rallatos C, Panayiotis Z, et al. Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy. Am J Ophthalmol. 2003;136:750–752
  18. Cardillo Piccolino F, Eandi CM, Ventre L, et al. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003;23:752–763
  19. Taban M, Boyer DS, Thomas EL, Taban M. Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol. 2004;137:1073–1080
  20. Schlotzer-Schrehardt U, Viestenz A, Naumann GO, et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol. 2002;240:748–757
  21. Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U, et al. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol. 2002;120:835–844
  22. Colucciello M. Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy. Retina. 2006;26:239–242
  23. Yaman A, Arikan G, Saatci AO, Cingil G. Choroidal neovascularization following photodynamic therapy in a patient with chronic central serous chorioretinopathy. Bull Soc Belge Ophtalmol. 2007;303:69–73
  24. Stewart JM. Half dose verteporfin PDT for central serous chorioretinopathy. Br J Ophthalmol. 2006;90:805–806
  25. Reibaldi M, Boscia F, Avitabile T, et al. Low-fluence photodynamic therapy in long-standing chronic central serous chorioretinopathy with foveal and gravitational atrophy. Eur J Ophthalmol. 2009;19:154–158
  26. Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci. 2006;47:371–376
  27. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin (One-year results of 2 randomized clinical trials. TAP report). Arch Ophthalmol. 1999;117:1329–1345
  28. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol. 1999;117:1161–1173
  29. Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration (2-year results of a randomized clinical trial). Arch Ophthalmol. 2005;123:448–457
  30. Chan WM, Lai TY, Lai RY, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina. 2008;28:85–93
  31. Lai TY, Chan WM, Lam DS. Transient reduction in retinal function revealed by multifocal electroretinogram following photodynamic therapy. Am J Ophthalmol. 2004;137:826–833
  32. Loo RH, Scott IU, Flynn , et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22:19–24
  33. Schmidt-Erfurth U, Schloetzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci. 2003;44:4473–4480
  34. Henderson BW, Gollnick SO, Snyder JW, et al. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res. 2004;64:2120–2126
  35. Framme C, Flucke B, Birngruber R. Comparison of reduced and standard light application in photodynamic therapy of the eye in two rabbit models. Graefes Arch Clin Exp Ophthalmol. 2006;244:773–781

PII: S0002-9394(09)00623-0

doi: 10.1016/j.ajo.2009.08.026

American Journal of Ophthalmology
Volume 149, Issue 2 , Pages 307-315.e2 , 1 February 2010

Article Tools

* Image Usage & Resolution